Technical corrections only. The engrossed version (v3) removes the strike-out and italicized text from the reported version (v2), presenting the final text as passed by the Senate. No substantive policy changes were made between these two versions.
National Plan for Epilepsy Act
- Sponsor
- Sen. Schmitt, Eric [R-MO]
- Committees
- Health, Education, Labor, and Pensions Committee (primary)
- Last action
- Aug 10, 2026
Bottom line
This bill mandates a comprehensive federal review and strategic update to improve epilepsy-related programs, research, and care coordination, aiming to enhance health outcomes for individuals with epilepsy.
What it actually does
This bill directs the Secretary of Health and Human Services (HHS) to conduct a comprehensive review of existing federal programs, activities, and strategic plans related to epilepsy research, prevention, early identification, diagnosis, and treatment. The Secretary is tasked with identifying knowledge gaps, improving health outcomes, and providing recommendations to Congress within two years, while also updating federal efforts as appropriate.
Proponents argue
Supporters argue this bill is a crucial step to address existing knowledge gaps, improve coordination across federal agencies, and ultimately enhance the lives of individuals with epilepsy and their caregivers by fostering better research, prevention, and treatment strategies. They emphasize the importance of a national, coordinated approach to a complex neurological condition.
Opponents contend
Critics, if any, might argue that the bill creates another bureaucratic review process without direct funding or immediate action, potentially duplicating existing efforts or diverting resources from direct patient care. They might also contend that such reviews are already part of agency mandates and do not require specific legislation.
The bill is very short and clear, allowing for quick comprehension by any interested reader.
Section 2(a)
Mandate for Comprehensive Review and Recommendations
This section requires the Secretary of Health and Human Services to conduct a thorough review of all existing federal programs, activities, and strategic plans related to epilepsy. The goal is to identify gaps in knowledge and services, and to provide recommendations to Congress on how to improve health outcomes for people with epilepsy. The Secretary is also tasked with updating these federal efforts as necessary.
Supporters argue
Supporters argue this provision is essential for a holistic and efficient approach to epilepsy care and research. By mandating a review, it ensures that federal efforts are not fragmented but are strategically aligned to address the most pressing needs and knowledge gaps, ultimately leading to better patient outcomes.
Critics contend
No specific opposition is typically raised against this provision as it focuses on review and coordination, which are generally seen as beneficial. Potential critics might argue it's an unfunded mandate or that agencies already conduct such reviews internally.
Tradeoffs
The primary tension is between the desire for comprehensive strategic planning and the potential for bureaucratic overhead. While coordination is valuable, the process itself requires resources and time that could otherwise be directed to immediate research or care.
Section 2(b)
Specific Areas for Review and Consideration
This section details the specific areas the Secretary must include in the review. These include assessing current evidence-based research, identifying knowledge gaps, reviewing existing federal programs for coordination opportunities, considering global efforts, setting near- and long-term goals, and evaluating federal investment. It also mandates considering opportunities to improve collaboration, prevent sudden unexpected death in epilepsy (SUDEP), enhance surveillance, and support new treatments and quality of life improvements.
Section 2(c) and 2(d)
Stakeholder Engagement and Congressional Report
This provision requires the Secretary to regularly convene and solicit input from other federal agencies and relevant stakeholders, including patient advocates and non-federal subject matter experts, to inform the review. Furthermore, within two years of the Act's enactment, the Secretary must submit a comprehensive report to specific Congressional committees detailing the review's findings, stakeholder feedback, recommendations for improved coordination, and any proposed changes to federal programs, including statutory barriers to implementation.